Clinical Trial Update: Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update for an anti-CEACAM5 antibody-drug conjugate (M9140) named Precemtabart Tocentecan in Chinese participants with solid tumors, including colo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• tocentecan (M9140, Precemtabart) anti-CEACAM5 ADC (tocentecan)

Snippet

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Conditions: Solid Tumors, Colorectal Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING